Mumbai, June 21, 2017: Pharma Major,Cadila Healthcare Ltd (Zydus Cadila) today said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.
It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, company said in a filing with BSE.
United News of India
